Navigation Links
Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
Date:12/10/2010

SAN ANTONIO Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900 patients with HER2-negative breast cancer treated with chemotherapy with or without bevacizumab.

"So far, no efficacy data from Phase III trials have been reported for early breast cancer. This will be the first," said von Minckwitz. "If the pathological complete response rate is higher with bevacizmab than without bevacizumab, it will provide a new option to improve neoadjuvant treatment in HER2-negative breast cancer."

Bevacizumab is currently approved in the United States in combination with paclitaxel for the first-line treatment of metastatic breast cancer. In July 2010, the Food and Drug Administration's Oncologic Drugs Advisory Committee voted 12 to 1 to eliminate this indication from the treatment label of bevacizumab.

"A negative or positive result might have a significant effect on this picture," said von Minckwitz. "However, pathological response as a surrogate for outcome is only confirmed for chemotherapy. Long-term follow up, as well as results from adjuvant studies have to be awaited."

The researchers investigated whether adding bevacizumab to treatment with four cycles of epirubicin/cyclophosphomide, followed by four cycles of docetaxel improved the rate of pathological complete response, which was defined as no invasive or non-invasive residual cancer in the breast or nodes.

Between May 2007 and June 2010, 944 patients were assigned chemotherapy treatment with epirubicin/cyclophosphamide followed by docetaxel; 945 patients were assigned
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... For nearly two decades, audiences around the world ... Deva Premal & Miten with their rapturous Nepali flute ... album in May, their 2014 MANTRAS FOR LIFE TOUR ... globe, including Russia, Ukraine, Israel, Australia, the U.S., Canada, ... new album and a new five-piece band, the love ...
(Date:8/27/2014)... positive hospital blood culture samples are discarded every day ... skin germs instead of specific disease-causing bacteria. , ... clinicians may be able to use the resistance profiles ... patients with antibiotics appropriate to their ailment, Tel Aviv ... Alon of TAU,s Sackler Faculty of Medicine and the ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According ... Market Research "Ablation Technologies Market (Applications: Cardiovascular, Gynecology, ... Electrical, Ultrasound, Microwave, Cryotherapy) - Global Industry Analysis, ... 2020," the global ablation technologies market was valued ... estimated to reach a market worth USD 10,611 ...
(Date:8/27/2014)... NH 8/27/14)Dartmouth cancer researchers developed and tested an ... environmental interactions that contribute to disease as published ... , The approach fills a gap in current ... complex interactions among genetic and environmental factors. When ... interactions versus those that reflect chance combinations among ...
(Date:8/27/2014)... 2014 Nava Beauty Store and Spa aims ... patrons from those seeking luxury care products to the everyday ... high end luxurious brands like Valmont and Elemis to cater ... brands like Dermalogica and Bliss to provide easy to use ... also offer purely organic skin care products such as Jurlique, ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:'Junk' blood tests may offer life-saving information 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Nava Beauty Store Announce Grand Opening in Great Neck, New York 2
... in the United States who undergo surgery to have ... a recent study shows that men who have their ... cancer returns . ,Researchers studied more than 500 ... study first had a radical prostatectomy and also underwent ...
... is the most common bacterial illness in children and ... of children may be getting treated unnecessarily with antibiotics ... they don’t need them may build up antibiotic resistance, ... a more serious infection. ,According to the new ...
... that certain hormones in the body may yield a ... events and death in people with no symptoms. Researchers ... the current standards used to diagnose heart failure. ... the participants’ blood looking for specific substances and compared ...
... their risk of birth defects. Now, new research shows ... say about 31,000 stroke-related deaths and about 17,000 heart ... fortification was implemented. ,Folic acid lowers homocysteine levels. ... risk for stroke and heart disease. Specialists from the ...
... new study shows the use of antibacterial products, such ... reduce the risk of infectious// disease symptoms in the ... households in New York with at least one preschool-age ... household cleaning and personal hygiene products that contained antibacterial ...
... study suggests drinking extra fluids may do more harm ... ,Researchers examined results from previous studies to determine if ... safe. Previous data has shown during a respiratory infection, ... large amounts of a specific hormone that conserves water. ...
Cached Medicine News:
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- Emergency ... design, blended emergency medical training and response technologies, ... defibrillator) training from the Department of Homeland ... Reserve 81 st Regional Support Command ... contract includes nationwide CPR/AED/First Aid training. The Army ...
(Date:8/27/2014)... , Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that certain members of the ... Healthcare Conference to be held September 8-10, 2014 in ... , Chief Executive Officer and President, is scheduled to ... portfolio at 10:55 a.m. ET on Wednesday, September 10, ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
... High Throughput Screening (UHTS), Analyst GT ... Allows for smooth transfer of assays ... sharing all the detection modalities of ... fluorescence polarization, time-resolved fluorescence, luminescence, absorbance, ...
... Ultra High Throughput Screening (UHTS), Analyst ... performance. Allows for smooth transfer of ... by sharing all the detection modalities ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ...
... exclusively for cell-based assays, the NOVOstar provides ... to the flexibility of an on-board reagent ... plate to plate or from three reagent ... the unit has two injectors that can ...
... cDNA and Oligonucleotides The Tecan GENios ... variety applications that are quantified by Fluorescence, Absorbance ... assays in Microplate formats from 6 to ... Cuvettes Independent whether you have to quantitate ...
Medicine Products: